Immunohbs

Human Hepatitis B Immunoglobulin, the active ingredient in Immunohbs, is an immunoglobulin presented as an injectable solution for intramuscular use. It provides passive immunity to individuals at risk of hepatitis B virus infection, particularly after known or suspected exposure.

GNH USA supplies Immunohbs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering cold‑chain logistics for biologic products.

Immunohbs, a human hepatitis B immunoglobulin, is used in the antiviral pathway to prevent HBV infection.

- Post‑exposure prophylaxis after known or suspected hepatitis B exposure: supplies anti‑HBs antibodies to immediately neutralize virus and reduce infection risk. - Prevention of hepatitis B infection in newborns of HBsAg‑positive mothers: provides passive immunity to lower vertical transmission rates. - Protection for individuals lacking adequate hepatitis B vaccine response: delivers immediate antibodies to bridge immunity gap.

Immunohbs may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain - Redness or swelling at the injection site - Mild fever - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Serum sickness–like illness - Hemolysis - Thromboembolic events - Severe hypotension - Acute renal failure

Before using Immunohbs, several precautionary measures should be observed to ensure safety and efficacy.

- Assess hepatitis B immunity: determine anti‑HBs status before administration. - Avoid in patients with known severe hypersensitivity to human immunoglobulins. - Use cautiously in individuals with IgA deficiency, as they may develop antibodies against IgA. - Monitor for signs of anaphylaxis during and after injection. - Consider risk‑benefit in pregnancy; safety not established. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunohbs can interact with other therapies, requiring attention to avoid reduced efficacy or increased adverse events.

Major Interactions (Avoid): - Concurrent administration of other blood products may increase volume overload risk. - Live vaccines given within 4 weeks may have diminished effectiveness. - Immunosuppressive agents may reduce the protective effect of the immunoglobulin.

Moderate Interactions (Monitor Closely): - Anticoagulants: may heighten bleeding tendency at the injection site. - Hepatitis B vaccine containing surface antigen: may interfere with serologic testing for vaccine response.